Human papillomavirus (HPV) is a known oncogenic virus associated with uterine cervical cancer, anogenital cancer, and oropharyngeal cancer. It has been proven that HPV proteins E6 and E7 can bind to p53 and retinoblastoma protein in epithelial cells and interact with growth-regulating system in uterine cervix, anus, and oropharynx \[[@b1-jptm-2016-07-08],[@b2-jptm-2016-07-08]\]. Almost all uterine cervical cancers and anal cancers are associated with HPV infection \[[@b1-jptm-2016-07-08]\]. HPV-mediated oropharyngeal squamous carcinomas have different disease entity from conventional oropharyngeal squamous carcinomas associated with chemical mutagens \[[@b3-jptm-2016-07-08]\]. However, the role of HPV in mammary carcinogenesis still remains controversial because various risk factors such as genetic predisposition, diet, hormonal status, life style, and their interactions are involved complexly in the pathogenesis of breast cancer \[[@b4-jptm-2016-07-08]\]. HPV infection has been reported in 4.4% to 60% of breast cancers \[[@b5-jptm-2016-07-08]-[@b29-jptm-2016-07-08]\]. Various subtypes of HPV including HPV-11, HPV-16, HPV-18, HPV-33, HPV-58, HPV-59, HPV-73, and HPV-82 are candidate subtypes of HPV associated with breast cancers. On the contrary, some studies could not detect HPV infection in breast cancers \[[@b30-jptm-2016-07-08]-[@b33-jptm-2016-07-08]\]. Furthermore, HPV infections have been detected not only in breast cancers, but also in various benign breast lesions such as fibroadenoma and intraductal papilloma. To the best of our knowledge, meta-analysis has not been performed yet to evaluate the relationship between HPV infection and breast cancer in a case-control setting. Therefore, the objective of this study was to perform meta-analysis between HPV infection and breast cancer to determine the prevalence of HPV-positivity in breast cancer, to determine whether any specific HPV subtypes are associated with breast cancer, and to evaluate the possibility of sexual transmission of HPV from genitals to breast.

MATERIALS AND METHODS
=====================

Meta-analysis
-------------

A systematic literature search was conducted in PubMed (January 1, 1992, to September 30, 2015) with the following keywords: "breast neoplasm" and "human papillomavirus." All potentially relevant studies were reviewed. Studies with case-control setting were selected. Analyses were performed using R ver. 3.2.2 (2015-08-14) statistical software.

Tumor samples
-------------

The study was performed with 123 breast cancers and nine intraductal papillomas. These patients received surgeries at Korea University Guro Hospital from January 2007 to January 2015. The study protocol was approved by the Institutional Review Board of Guro Hospital. The 123 breast cancer samples were composed of 106 formalin-fixed and paraffin embedded (FFPE) tissues and 17 touch imprint cytology samples. The patients who received mastectomy and nipple resection were preferentially selected to obtain FFPE nipple tissues. The touch imprint cytology samples were also used to compare FFPE tissues and cytology samples. The nine intraductal papillomas samples were composed of nine FFPE tissues. To define the infection route by detecting HPV in nipple, 13 FFPE nipple tissues of breast cancer patients who had been confirmed with HPV infection in uterine cervix were included in this study. All materials were obtained from the tissue bank of Korea University Guro Hospital. Medical records and pathological reports of patients and histological features of breast cancer enrolled in this study were reviewed.

DNA isolation
-------------

Two or three 10-μm sections were taken from FFPE tissues. Deparaffinization of these sections was sufficiently done by xylene and ethanol treatment for 5 minutes alternately for three times. DNA was extracted using QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instruction. The concentration of extracted DNA was measured on Nanodrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). The quality of DNA was determined by evaluating A260/A280 ratio. DNA isolation from touch imprint sample from fresh breast cancer was also performed with QIAamp DNA Mini Kit according to the manufacturer's instruction.

Real-time polymerase chain reaction
-----------------------------------

Extracted DNA samples were subject to real-time polymerase chain reaction (PCR) with gene specific primers provided with Anyplex II HPV 28 Detection System (Seegene, Seoul, Korea) using CFX96 Real-Time PCR (Bio-Rad, Hercules, CA, USA). Melting curves were analyzed using the exclusive analysis program provided with the Anyplex II HPV 28 Detection System. This system is able to detect 28 subtypes of HPV, including all subtypes reported in the literatures, such as HPV-11, HPV-16, HPV-18, HPV-33, HPV-58, HPV-59, HPV-73, and HPV-82. Because the Anyplex II HPV 28 Detection System was originally designed for cytological samples swabbed in uterine cervix, verification of Anyplex II HPV 28 Detection System with FFPE tissue of uterine cervical squamous cell carcinoma was performed.

RESULTS
=======

Meta-analysis
-------------

Twenty-two case-control studies for HPV infection in breast cancer were enrolled in meta-analysis with random effect model. HPV infection was detected in 342 of 1,833 breast cancers and in 36 of 857 benign breast lesions ([Table 1](#t1-jptm-2016-07-08){ref-type="table"}). The overall odds ratio between breast cancer and HPV infection was 5.43 (95% confidence interval, 3.24 to 9.12) with I^2^=34.5% ([Fig. 1](#f1-jptm-2016-07-08){ref-type="fig"}). This result was statistically significant.

Clinicopathologic data
----------------------

The median age of 123 breast cancer patients was 51.6 years (range, 23 to 79 years). The 123 breast cancers included 103 invasive carcinomas of no special type, five invasive lobular carcinomas, one microinvasive carcinoma, three ductal carcinomas *in situ*, and 11 carcinomas of other specific subtypes. Other clinicopathological characteristics of the 123 cases of breast cancer are summarized in [Table 2](#t2-jptm-2016-07-08){ref-type="table"}.

Of the 13 cases whose FFPE nipple tissues were tested for HPV, one case was positive for HPV-16 infection in uterine cervix and 12 cases were positive for HPV infection in uterine cervix by Hybrid Capture 2 (Qiagen, Gaithersburg, MD, USA) ([Table 3](#t3-jptm-2016-07-08){ref-type="table"}). Of these 13 cases, five had low-grade squamous intraepithelial lesions, one had high-grade squamous intraepithelial lesion, and one had endocervical type adenocarcinoma in uterine cervix.

Availability of Anyplex II HPV 28 Detection System in FFPE tissue
-----------------------------------------------------------------

HPV-16 was detected in the FFPE tissue of uterine cervical squamous cell carcinoma using Anyplex II HPV 28 Detection System, in concordance with the result of cytology sample using Anyplex II HPV 28 Detection System, proving that Anyplex II HPV 28 Detection System worked properly for FFPE tissue as for the cytology specimen. Therefore, Anyplex II HPV 28 Detection System can be used to detect HPV infection in FFPE tissue.

Real-time PCR
-------------

Proper DNA samples were isolated from 106 FFPE breast cancers, 17 touch imprint cytology samples of breast cancer, 13 FFPE nipple tissues, and nine FFPE intraductal papillomas. Amplification of dissociation curve of HPV subtypes 6, 16, 33, 39, 40, 51, 53, 58, and 61 was detected in real-time PCR of 22 FFPE breast cancers (17.9%) ([Fig. 2](#f2-jptm-2016-07-08){ref-type="fig"}). The 22 cases included 19 cases of invasive carcinoma of no special type, one case of adenoid cystic carcinoma, one case of metaplastic carcinoma, and one case of apocrine carcinoma ([Table 4](#t4-jptm-2016-07-08){ref-type="table"}). Histological features of HPV infection were not identified by slide review of these 22 cases. In two FFPE tissues of intraductal papilloma, amplification of dissociation curve of HPV-33 and HPV-53 was detected in real-time PCR (22.2% of nine intraductal papilloma FFPE tissues). However, because HPV-positive cases showed weak amplification of the dissociation curve, these results were considered as weak positivity for HPV. HPV was not detected in 17 touch imprint cytology samples of breast cancer or 13 FFPE tissues of nipple.

DISCUSSION
==========

Genetic and environmental factors such as mutation in *BRCA1/2*, ethnicity, hormonal effect, diet, and ionizing radiation are known to be involved in the carcinogenesis of breast cancer. However, two-thirds of patients with breast cancer have no association with these risk factors \[[@b37-jptm-2016-07-08]\]. To elucidate viral carcinogenesis in mammary cancer development, many studies have focused on oncogenic virus. According to multistep carcinogenesis model of breast cancer, *TP53* is considered as one predisposing gene. Because HPV E6 and E7 oncoproteins are able to inactivate *TP53* gene, HPV can play a role in this multistep mammary carcinogenesis. On the other hand, Ohba *et al*. \[[@b38-jptm-2016-07-08]\] have suggested that HPV infection induces overexpression of APOBEC3B associated with the early stage of carcinogenesis in breast cancer.

Recently, many studies have been performed to prove the relationship between breast cancer and HPV infection. These studies have revealed that approximately 19.8% of HPV infections are in breast cancer (range, 0% to 60%). The causes of no detection of HPV infection include geographic factors due to race and prevalence of HPV infection, selection bias due to difference in prevalence, and too low viral load to be technically detectable. At present, most studies performed in China and Middle East have showed high prevalence of positivity for HPV in breast cancer.

Meta-analysis from case-control setting revealed that the prevalence of HPV infection in breast cancer was higher than that in benign breast lesion. The I^2^ was appropriate for random effect model. The overall odds ratio between breast cancer and HPV infection was statistically significant. However, there are some limitations of meta-analysis. First, publication bias might exist due to low prevalence of HPV infection in breast cancers. Many studies that failed to detect HPV in breast cancer might not have been reported in the literature. Moreover, because 22 studies were performed with different methods that could only detect limited HPV subtypes, the prevalence of HPV infection in breast cancer might have been underestimated. Therefore, the quality of data from the literature might be questionable.

We found that variable HPV subtypes were detected in 22 of 123 Korean breast cancers by real-time PCR. Specific HPV subtypes including HPV-39, HPV-40, HPV-53, and HPV-61 have not been mentioned in the literature. HPV-51 was the most frequently found subtype. It was detected in 14 of 22 HPV-positive breast cancers. HPV-16 and HPV-18 were the most frequently found subtypes in cervical cancer and oropharyngeal cancer. However, they were not common HPV subtypes in breast cancer. They were not detected in the two intraductal papillomas either. If HPV infection is involved in carcinogenesis of breast, specific HPV subtypes hardly related in cervical cancer and oropharyngeal cancer can have a role as carcinogen in breast. Interestingly, this result showed that the prevalence of HPV infection in benign breast lesions (22.2%) was higher than that in breast cancers (17.9%), although meta-analysis supported correlation between breast cancer and HPV. However, because only nine intraductal papillomas were tested, this result might have been compromised.

It is important to note that most cases showed weak positivity for HPV. Fragmentation of extracted DNA in FFPE tissues could be one of the reasons responsible for this result. However, even when the reduction of positivity by fragmentation was considered, positivity for HPV in FFPE breast cancer samples was too weak. Khan *et al*. \[[@b39-jptm-2016-07-08]\] have also found HPV DNA in 26 of 124 Japanese breast cancer patients by PCR for FFPE breast cancer samples. Because the viral load in breast cancers was very low compared to viral load examined in uterine cervical carcinoma, they concluded that HPV was not involved in the development of breast cancers in Japanese. Due to the weak positivity of HPV in this study, we also concluded that this result was not a significant evidence to support carcinogenesis of HPV in breast.

If HPV is involved in the development of breast cancer, some differences between HPV-positive and HPV-negative breast cancers should be present. Heng *et al*. \[[@b13-jptm-2016-07-08]\] have found putative koilocytes as the proof of HPV infection in HPV-positive breast cancers. However, Khan *et al*. \[[@b39-jptm-2016-07-08]\] reviewed all HPV-positive breast cancer and failed to find koilocytes. In this study, we also failed to find koilocytes after slide review of the 123 breast cancers and nine intraductal papillamas. Kan *et al*. \[[@b40-jptm-2016-07-08]\] have reported that HPV-positive breast cancers are not correlated with grade, patient survival, hormonal receptor status, HER-2 expression, or p53 overexpression. The characteristics of HPV-positive breast cancer are still controversial.

Since HPV is known as a sexually transmitted virus, HPV may be transmitted to the breast tissue through nipple by sexual behavior. We didn't detect HPV infection in 13 nipple FFPE tissues and FFPE breast cancers of patients who had HPV infection in uterine cervix ([Table 3](#t3-jptm-2016-07-08){ref-type="table"}) and failed prove that nipple was the infection route. However, Glenn *et al*. \[[@b17-jptm-2016-07-08]\] have suggested that HPV can be detected in the epithelial cells extracted from human milk. In addition, de Villiers *et al*. \[[@b41-jptm-2016-07-08]\] have detected HPV infection in nipple tissues. Some studies have tried to prove the coexistence of HPV infection in both cervical lesion and breast cancer. Hennig *et al*. \[[@b6-jptm-2016-07-08]\] have proved that HPV-16 positive breast cancer is corresponding to HPV-16 positive high-grade cervical intraepithelial neoplasia in 19 of 41 cases. On the contrary, Lv *et al*. \[[@b42-jptm-2016-07-08]\] failed to find coexistence of HPV in breast or cervical tissues of 12 cases. In our study, there was no case of HPV coexistence in cervical lesion or breast cancer. Furthermore, although most cervical and oropharyngeal cancers are provoked by HPV-16 and HPV-18, and HPV-16 was found in one breast cancer only. Common infected HPV subtypes of breast cancer might be different from those of cervical and oropharyngeal cancers. It is not convincing that the cervical intraepithelial neoplasia is one of the risk factors of breast cancer.

Statistical significance of correlation between breast cancer and HPV was found in meta-analysis using published studies of case-control setting. In addition, we detected 22 HPV-positive breast cancers in 123 Korean patients and two HPV-positive intraductal papillomas in nine Korean patients without finding histological characteristics of HPV infection in breast cancers. Because all HPV-positive breast cancers showed weak positivity, a correlation between HPV and breast cancer was not confirmed in this study. Further study with larger epidemiologic population is necessary to elucidate the role of HPV in mammary carcinogenesis.
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###### 

The published studies of HPV and breast cancer in case-control setting

  Study                                                        Country        Case (n = 1,833)   Control (n = 893)        
  ------------------------------------------------------------ -------------- ------------------ ------------------- ---- -----
  Bratthauer *et al.* \[[@b34-jptm-2016-07-08]\] (1992)        USA            0                  28                  0    15
  Yu *et al.* \[[@b5-jptm-2016-07-08]\] (1999)                 China, Japan   18                 34                  1    19
  Damin *et al.* \[[@b7-jptm-2016-07-08]\] (2004)              Brazil         25                 76                  0    41
  Tsai *et al.* \[[@b8-jptm-2016-07-08]\] (2005)               Taiwan         8                  54                  2    42
  Choi *et al.* \[[@b9-jptm-2016-07-08]\] (2007)               Korea          8                  115                 0    31
  de Leon *et al.* \[[@b11-jptm-2016-07-08]\] (2009)           Mexico         15                 36                  0    43
  He *et al.* \[[@b12-jptm-2016-07-08]\] (2009)                China          24                 16                  1    19
  Heng *et al.* \[[@b13-jptm-2016-07-08]\] (2009)              Australia      8                  20                  3    25
  Mendizabal-Ruiz *et al.* \[[@b14-jptm-2016-07-08]\] (2009)   Mexico         3                  64                  0    40
  Mou *et al.* \[[@b15-jptm-2016-07-08]\] (2011)               China          4                  58                  0    46
  Chang *et al.* \[[@b35-jptm-2016-07-08]\] (2012)             China          0                  48                  0    30
  Frega *et al.* \[[@b16-jptm-2016-07-08]\] (2012)             Italy          9                  22                  0    12
  Glenn *et al.* \[[@b17-jptm-2016-07-08]\] (2012)             Australia      35                 42                  11   47
  Sigaroodi *et al.* \[[@b18-jptm-2016-07-08]\] (2012)         Iran           15                 43                  1    40
  Liang *et al.* \[[@b19-jptm-2016-07-08]\] (2013)             China          48                 176                 6    31
  Ali *et al.* \[[@b23-jptm-2016-07-08]\] (2014)               Iraq           60                 69                  3    41
  Ahangar-Oskouee *et al.* \[[@b24-jptm-2016-07-08]\] (2014)   Iran           22                 43                  0    65
  Manzouri *et al.* \[[@b25-jptm-2016-07-08]\] (2014)          Iran           10                 45                  7    44
  Peng *et al.* \[[@b26-jptm-2016-07-08]\] (2014)              China          2                  98                  0    50
  Fu *et al.* \[[@b36-jptm-2016-07-08]\] (2015)                China          25                 144                 1    82
  Vernet-Tomas *et al.* \[[@b33-jptm-2016-07-08]\] (2015)      Spain          0                  76                  0    2
  Li *et al.* \[[@b28-jptm-2016-07-08]\] (2015)                China          3                  184                 0    92
  Total                                                                       342                1491                36   857

HPV, human papillomavirus.

###### 

Clinicopathological characteristics of 123 cases of breast cancer

  Characteristic                          Criteria                                No.
  --------------------------------------- --------------------------------------- -----
  Age                                     34--50                                  67
  51--66                                  56                                      
  Median (range)                          51.6 (23--79)                           
  Operation type                          Mastectomy                              108
  Conserving operation                    15                                      
  Histologic grade                        Grade 1                                 27
  Grade 2                                 41                                      
  Grade 3                                 52                                      
  Hormonal receptor                       ER positive                             69
  PR positive                             62                                      
  HER2 positive                           52                                      
  Triple negative                         25                                      
  Lymph node metastasis                   Positive                                54
  Negative                                69                                      
  HPV detection in cervix                 Positive                                54
  Negative                                69                                      
  Histologic type                         Invasive carcinoma of no special type   103
  Invasive lobular carcinoma              5                                       
  Microinvasive carcinoma                 1                                       
  Ductal carcinoma *in situ*              3                                       
  Metaplastic carcinoma                   2                                       
  Carcinoma with medullary feature        2                                       
  Apocrine carcinoma                      2                                       
  Carcinoma with neuroendocrine feature   1                                       
  Adenoid cystic carcinoma                1                                       
  Mucinous carcinoma                      1                                       
  Micropapillary carcinoma                1                                       

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HPV, human papillomavirus.

###### 

Clinicopathologic data of breast cancer patients confirmed HPV infection in uterine cervix

  Case No.   Age of breast surgery (yr)   Histology of breast         Age of HPV detection at uterine cervix (yr)   Histology of uterine cervix         Method
  ---------- ---------------------------- --------------------------- --------------------------------------------- ----------------------------------- -------------------------
  15         50                           Invasive carcinoma of NST   54                                            NI                                  HC2
  16         44                           Metaplastic carcinoma       44                                            LSIL                                HC2
  17         43                           Invasive carcinoma of NST   44                                            LSIL                                HC2
  18         48                           Invasive carcinoma of NST   48                                            NI                                  HC2
  19         50                           Invasive carcinoma of NST   50                                            NI                                  HC2
  20         46                           Invasive carcinoma of NST   46                                            LSIL                                HC2
  21         43                           Invasive carcinoma of NST   41                                            NI                                  HC2
  22         49                           Invasive carcinoma of NST   49                                            NI                                  HC2
  23         44                           Invasive carcinoma of NST   44                                            LSIL                                HC2
  24         63                           Invasive carcinoma of NST   60                                            Adenocarcinoma, endocervical type   HC2
  25         50                           Invasive carcinoma of NST   50                                            NI                                  Medical record (HPV-16)
  38         56                           Invasive carcinoma of NST   47                                            LSIL                                HC2
  56         57                           Invasive carcinoma of NST   46                                            HSIL                                HC2

HPV, human papillomavirus; NST, no special type; NI, in the biopsy, uterine cervical lesion was not identified; HC2, Hybrid Capture 2 (QIAGEN, Gaithersburg, MD, USA) in cytology sample; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions.

###### 

Clinicopathologic data and HPV subtype of HPV-positive breast cancer

  Case No.   Age (yr)   Sample   Histologic type             HPV subtype
  ---------- ---------- -------- --------------------------- ----------------
  1          50         FFPE     Invasive carcinoma of NST   33
  3          46         FFPE     Invasive carcinoma of NST   33
  8          55         FFPE     Adenoid cystic carcinoma    40, 51, 61
  9          63         FFPE     Metaplastic carcinoma       40, 51, 53, 61
  17         23         FFPE     Invasive carcinoma of NST   40, 51, 53, 61
  20         32         FFPE     Invasive carcinoma of NST   51, 53
  30         47         FFPE     Invasive carcinoma of NST   40, 51, 58
  39         44         FFPE     Invasive carcinoma of NST   51
  40         40         FFPE     Invasive carcinoma of NST   33, 51, 53
  41         49         FFPE     Invasive carcinoma of NST   51, 53
  49         55         FFPE     Invasive carcinoma of NST   51
  50         38         FFPE     Invasive carcinoma of NST   51
  63         70         FFPE     Invasive carcinoma of NST   6, 51, 58
  73         42         FFPE     Invasive carcinoma of NST   6, 40, 53
  74         58         FFPE     Invasive carcinoma of NST   6, 51
  75         54         FFPE     Invasive carcinoma of NST   51
  81         65         FFPE     Invasive carcinoma of NST   6, 40
  93         35         FFPE     Invasive carcinoma of NST   53
  99         54         FFPE     Invasive carcinoma of NST   6
  109        50         FFPE     Invasive carcinoma of NST   51
  120        63         FFPE     Apocrine carcinoma          16
  122        50         FFPE     Invasive carcinoma of NST   39

HPV, human papillomavirus; FFPE, formalin-fixed and paraffin embedded tissue; NST, no special type.
